Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

inalimarev

A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:recombinant vaccinia-CEA-MUC1-TRICOM vaccine
recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
rVaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
vaccinia-CEA-MUC-1-TRICOM vaccine
US brand name:PANVAC-V
Abbreviation:vCEA-MUC-1-TRI
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search